The Grünenthal Group: International, successful, innovative

Who we are...

The Grünenthal Group is an entrepreneurial, science-based pharmaceutical company specialized in pain, gout and inflammation.

Our ambition is to deliver four to five new products to patients in diseases with high unmet medical need by 2022 and become a €2 billion company.

We are a fully integrated research & development company with a long track record of bringing innovative pain treatments and state-of-the-art technologies to patients. By sustainably investing in our R&D above the industrial average, we are strongly committed to innovation.

Grünenthal is an independent, family-owned company headquartered in Aachen, Germany. We are present in 32 countries with affiliates in Europe, Latin America and the US. Our products are sold in more than 155 countries and approx. 5,500 employees are working for the Grünenthal Group worldwide.

In 2016, Grünenthal achieved revenues of approx. €1.4 bn..

... and what we do

  • In-licensing or Acquisition of Projects defined in our Areas of Interest in various development stages (from research to launched products) and countries
  • Out-Licensing/ Partnerships or Divestments in selected countries in different development stages
  • Co-Promotion/Co-Marketing Agreements for approved products
  • Alliance Management: A dedicated contact person for all partner relationships on  strategic, contractual and other general matters between the two parties.